CFTR and cystic fibrosis: Advances in antibiotic treatment of lung infections, improved nutrition, and most recently the use of highly effective CFTR modulator drug combinations (particularly ivacaftor/tezacaftor/electocaftor for the common F508del variant) has markedly extended the median lifespan on patients with CF from 36 years in 2006 to 53 years in 2021, with a marked improvement in lung function and decreased exacerbations.